Parkinson's disease cell therapy (Titan)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameParkinson's disease cell therapy (Titan)
Drug Alias NameSpheramineTC-15
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Retinal pigment epithelial cell therapy
Mechanisms of ActionDopamine receptors agonists
TargetsDopamine receptors
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanySpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTitan Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTitan Pharmaceuticals IncBayer AG
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A